These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38577174)

  • 1. PRaG 3.0 therapy for human epidermal growth factor receptor 2-positive metastatic pancreatic ductal adenocarcinoma: A case report.
    Kong YH; Xu ML; Zhang JJ; Chen GQ; Hong ZH; Zhang H; Dai XX; Ma YF; Zhao XR; Zhang CY; Chen RZ; Xing PF; Zhang LY
    World J Gastroenterol; 2024 Mar; 30(9):1237-1249. PubMed ID: 38577174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NAB-paclitaxel and gemcitabine in metastatic pancreatic ductal adenocarcinoma (PDAC): from clinical trials to clinical practice.
    De Vita F; Ventriglia J; Febbraro A; Laterza MM; Fabozzi A; Savastano B; Petrillo A; Diana A; Giordano G; Troiani T; Conzo G; Galizia G; Ciardiello F; Orditura M
    BMC Cancer; 2016 Sep; 16(1):709. PubMed ID: 27590845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nab-paclitaxel plus S-1 versus nab-paclitaxel plus gemcitabine as first-line chemotherapy in patients with advanced pancreatic ductal adenocarcinoma: a randomized study.
    Zong Y; Yuan J; Peng Z; Lu M; Wang X; Shen L; Zhou J
    J Cancer Res Clin Oncol; 2021 May; 147(5):1529-1536. PubMed ID: 33191450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
    Ellenrieder V; König A; Seufferlein T
    Digestion; 2016; 94(1):44-9. PubMed ID: 27438590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma.
    Shui L; Cheng K; Li X; Shui P; Zhou X; Li J; Yi C; Cao D
    BMC Cancer; 2020 Jul; 20(1):636. PubMed ID: 32646394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel.
    Sams L; Kruger S; Heinemann V; Bararia D; Haebe S; Alig S; Haas M; Zhang D; Westphalen CB; Ormanns S; Metzger P; Werner J; Weigert O; von Bergwelt-Baildon M; Rataj F; Kobold S; Boeck S
    Clin Transl Oncol; 2021 Nov; 23(11):2394-2401. PubMed ID: 33876417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durable Response and Good Tolerance to the Triple Combination of Toripalimab, Gemcitabine, and Nab-Paclitaxel in a Patient With Metastatic Pancreatic Ductal Adenocarcinoma.
    Shui L; Cheng K; Li X; Shui P; Li S; Peng Y; Li J; Guo F; Yi C; Cao D
    Front Immunol; 2020; 11():1127. PubMed ID: 32636837
    [No Abstract]   [Full Text] [Related]  

  • 8. Nano albumin bound-paclitaxel in pancreatic cancer: Current evidences and future directions.
    Giordano G; Pancione M; Olivieri N; Parcesepe P; Velocci M; Di Raimo T; Coppola L; Toffoli G; D'Andrea MR
    World J Gastroenterol; 2017 Aug; 23(32):5875-5886. PubMed ID: 28932079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma.
    Noel M; O'Reilly EM; Wolpin BM; Ryan DP; Bullock AJ; Britten CD; Linehan DC; Belt BA; Gamelin EC; Ganguly B; Yin D; Joh T; Jacobs IA; Taylor CT; Lowery MA
    Invest New Drugs; 2020 Jun; 38(3):800-811. PubMed ID: 31297636
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
    Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
    JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma.
    Rogers JE; Mizrahi JD; Xiao L; Mohindroo C; Shroff RT; Wolff R; Varadhachary GR; Javle MM; Overman M; Fogelman DR; Raghav KPS; Pant S; McAllister F
    Cancer Med; 2020 Aug; 9(15):5406-5415. PubMed ID: 32519420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
    BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interstitial lung disease in advanced pancreatic ductal adenocarcinoma patients treated with gemcitabine and nab-paclitaxel combination therapy: a retrospective analysis.
    Irie H; Suzuki R; Takagi T; Sugimoto M; Konno N; Sato Y; Hikichi T; Nakamura J; Hashimoto M; Ohira H
    Cancer Chemother Pharmacol; 2020 Mar; 85(3):517-523. PubMed ID: 31691078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
    Bachet JB; Hammel P; Desramé J; Meurisse A; Chibaudel B; André T; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Meyer VG; Taieb J; Volet J; Monier A; Bonnetain F; Louvet C
    Lancet Gastroenterol Hepatol; 2017 May; 2(5):337-346. PubMed ID: 28397697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a MUC5AC Antibody (NPC-1C) Administered With Second-Line Gemcitabine and Nab-Paclitaxel on the Survival of Patients With Advanced Pancreatic Ductal Adenocarcinoma: A Randomized Clinical Trial.
    Huffman BM; Basu Mallick A; Horick NK; Wang-Gillam A; Hosein PJ; Morse MA; Beg MS; Murphy JE; Mavroukakis S; Zaki A; Schlechter BL; Sanoff H; Manz C; Wolpin BM; Arlen P; Lacy J; Cleary JM
    JAMA Netw Open; 2023 Jan; 6(1):e2249720. PubMed ID: 36602796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial.
    Reni M; Zanon S; Peretti U; Chiaravalli M; Barone D; Pircher C; Balzano G; Macchini M; Romi S; Gritti E; Mazza E; Nicoletti R; Doglioni C; Falconi M; Gianni L
    Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):691-697. PubMed ID: 30220407
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination treatment with anti-HER2 therapeutic antibody RC48, PD-1 inhibitor, radiotherapy, and granulocyte macrophage-colony stimulating factor (GM-CSF) in patient with metastatic gastric cancer: a case report.
    Liu Z; Wang F; Zhang Y; Lu J; Yang Y
    Front Immunol; 2024; 15():1321946. PubMed ID: 38361930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase Ib/II study of gemcitabine, nab-paclitaxel, and pembrolizumab in metastatic pancreatic adenocarcinoma.
    Weiss GJ; Blaydorn L; Beck J; Bornemann-Kolatzki K; Urnovitz H; Schütz E; Khemka V
    Invest New Drugs; 2018 Feb; 36(1):96-102. PubMed ID: 29119276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination chemotherapy with gemcitabine and nab-paclitaxel for a metastatic pancreatic ductal adenocarcinoma patient undergoing hemodialysis.
    Kaneko T; Sugimori K; Tozuka Y; Fukushima T; Okada K; Oka H; Okazaki H; Maeda S
    Clin J Gastroenterol; 2019 Oct; 12(5):484-489. PubMed ID: 30993653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer.
    Rajeshkumar NV; Yabuuchi S; Pai SG; Tong Z; Hou S; Bateman S; Pierce DW; Heise C; Von Hoff DD; Maitra A; Hidalgo M
    Br J Cancer; 2016 Aug; 115(4):442-53. PubMed ID: 27441498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.